A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin- clavulanate

American Journal of Medicine

Volumn 105, Issue 3, 1998, Pages 182-191

  Gilbert, David N ^a,c   Lee, Belle L ^b   Dworkin, Ronald J ^a   Leggett, James L ^a   Chambers, Henry F ^b   Modin, Gunnar ^b   Täuber, Martin G ^b   Sande, Merle A ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GENTAMICIN; TIMENTIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLAVULANIC ACID; COCHLEA; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENTAMICINS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PENICILLINS; TICARCILLIN; TREATMENT OUTCOME;

EID: 0032169380     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00244-7     Document Type: Article

References (51)

1. 1. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991;35:399-405.
2. 2. Gilbert DN. Aminoglycosides. In: Mandell G, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995:279-305.
3. 3. Gilbert DN. Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:816-819.
4. 4. Klastersky J, Prevost JM, Meunier-Carpentier F, et al. Comparative trials of single dose versus twice daily sisomicin in bacteriuric patients. J Clin Pharmacol. 1997;17:520-528.
5. 5. Nordstrom L, Ringberg H, Cronberg S, et al. Does administration of an aminoglycoside in single daily dose affect its efficacy and toxicity? J Antimicrob Chemother. 1990;25:159-173.
6. 6. Hansen M, Achen F, Carstensen C, et al. Once-versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. J Drug Develop. 1988;1(suppl 3):119-124.
7. 7. Muijsken MA, Vreede RW, Van Dijk WC, et al. A randomized clinical study of efficacy and safety of once daily versus conventional dosing of netilmicin in patients with severe infections. J Drug Develop. 1988;1(suppl 3):145-146.
8. 8. Tulkens PM, Clerckx-Braun F, Donnez TJ, et al. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Develop. 1988;1(suppl 3):71-83.
9. 9. Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother. 1989;23:773-783.
10. 10. Mauracher EH, Lau WY, Kartowisastro H, et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther. 1989;11:604-613
11. 11. Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989; 159:931-937.
12. 12. DeVries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once-daily versus thrice daily netilmicin regimens in patients with intra-abdominal infections. Eur J Clin Microbiol Infect Dis. 1990;9:161-168.
13. 13. Ter Braak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990;89:58-66.
14. 14. Giamarellou H, Yiallouros K, Petrikkos G, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother. 1991;27(suppl C):73-79.
15. 15. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once-versus twice-daily amikacin dosing in critically ill adult and pediatric patients. J Antimicrob Chemother. 1991;28:753-764.
16. 16. Van de Auwera P, Meunier J, Ibrahim S, et al. Pharmacodynamic and toxicity of netilmicin (5 mg/kg/day) given once daily or in three divided doses to cancer patients with urinary tract infections. Antimicrob Agents Chemother. 1991;35:640-647.
17. 17. Vigano A, Principi N, Brivio L, et al. Comparison of 5 mg of netilmicin per kilogram of body weight once daily versus 2 mg per kilogram thrice daily for treatment of gram negative pyelonephritis in children. Antimicrob Agents Chemother. 1991;36:1499-1503.
18. 18. Gonzalez P, Aguado JM, Martin MA. Once-daily aminoglycoside dosing. Lancet. 1993;341:895. Letter.
19. 19. Maller R, Ahrne H, Holmen C, et al. Once-versus twice-daily amikacin regimen. Efficacy and safety in systemic gram-negative infections. J Antimicrob Chemother. 1993;31:939-948.
20. 20. Vanhaeverbeek M, Siska G, Douchamps J, Herchuelz A. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol. 1993;31:153-156.
21. 21. Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol. 1993;58:63-72.
22. 22. Mendes da Costa P, Kaufman L. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery. Hepatogastroenterology. 1992;39:350-354.
23. 23. Fan ST, Law WY, Teoh-Chan CH, et al. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother. 1988;22:69-74.
24. 24. Prins JM, Buller HP, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infection. Lancet. 1993;341: 335-339.
25. 25. Raz R, Adawi M, Romano S. Intravenous administrations of gentamicin only daily versus thrice daily in adults. Eur J Clin Microb Infect Dis. 1995;14:88-91.
26. 26. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother. 1993;31:585-598.
27. 27. Ibrahim S, Derde MP, Kaufman L, et al. Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease. Ren Fail. 1990;12:199-203.
28. 28. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med. 1993;199:584-593.
29. 29. Maller R, Isaksson B, Nilsson L, Soren L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother. 1998;22:75-79.
30. 30. Vreede D. Infections by Gram-negative Bacilli: Humoral Defense of the Host and Antimicrobial Therapy. Utrecht, Netherlands: Drukkerij Elinkwijg BV; 1988;143-165.
31. 31. Blaser J, Simmen HP, Thrunheer U, et al. Nephrotoxicity. High frequency ototoxicity , efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. J Antimicrob Chemother. 1995;36:803-814.
32. 32. Koo J, Tight R, Rajkumar V, Hawa Z. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med. 1996;101:177-183.
33. 33. Elhanan K, Siplovich L, Ra R. Gentamicin once-daily versus thrice-daily in children. J Antimicrob Chemother. 1995;35:327-332.
34. 34. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
35. 35. Schwartz SN, Pazen GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis. 1978;138:499-505.
36. 36. Nicolau DP, Freeman DC, Belliveau PB, et al. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother. 1995;39:650-655.
37. 37. Freeman C, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39:677-686.
38. 38. Jolley ME, Stroupe SD, Wang CH et al. Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin Chem. 1981;27:1190-1197.
39. 39. Sawchuk R, Zaske D. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokin Biopharm. 1976;4:183-195.
40. 40. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13: 818-829.
41. 41. Perrone RD, Madras NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38: 1933-1953.
42. 42. The EORTC International Antimicrobial Therapy Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis. 1978;137:14-29.
43. 43. Klastersky J, Hensgrens C, Debusscher I. Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillincephalothin, and cephalothin-tobramycin. Antimicrob Agents Chemother. 1975;7:640-645.
44. 44. Barza M. Ioannidis JPA, Cappeleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312:338-345.
45. 45. Munckhof WJ, Grayson J, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645-663.
46. 46. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996; 124:717-725.
47. 47. Galloe AM, Guadal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol. 1995;48:39-43.
48. 48. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Systems Pharm. 1996;53:1141-1150.
49. 49. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:786-795.
50. 50. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:796-809.
51. 51. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis. 1997;24:810-815.